EGFR and non-small cell lung carcinoma: Based on these previous reports, we analyzed the data of EGFR-mutant NSCLC patients to compare the PFS and proportion of acquisition of T790M after first-line treatment with EGFR-TKIs in patient groups with and without PD-L1 expression.